A new large-scale analysis found that the short-term cardiovascular and metabolic side effects of antidepressants vary widely ...
ANN ARBOR, Mich., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that an oral presentation and a poster presentation have been accepted for presentation at the AHA ...
Brekiya® autoinjector, a new specialty therapy from Amneal, is now available for prescription exclusively through Walgreens Specialty Pharmacy ...
With Eli Lilly's recent acquisition of Verve Therapeutics and its PCSK9 candidate, delve into what the target represents.
Incyte (Nasdaq:INCY) today announced new data from the Phase 3b TRuE-AD4 study evaluating the efficacy and safety of Opzelura ® (ruxolitinib cream) in adults with moderate atopic dermatitis (AD) who ...
Widespread contamination of performance supplements with undeclared anabolic steroids demands stronger detection systems and ...
Joel S. Schuman, MD, FACS, of Wills Eye Hospital, presented an update on laser therapies for glaucoma, emphasizing recent ...
Millions of Americans take antidepressants. And like all medication they come with side effects. Researchers studied 30 ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced plans to present new research from the company’s cardio-pulmonary portfolio and pipeline at the American Heart ...
You might be doing everything right, popping your tablets, eating “healthy,” cutting down on salt, and yet your BP monitor ...
FMC-376 demonstrated robust anti-tumor activity across preclinical models and led to deeper inhibition of KRAS downstream ...
Esperion (NASDAQ: ESPR) today announced it will report third quarter 2025 financial results before the market opens on Thursday, November 6, 2025. Following the release, management will host a webcast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback